Oliver Lenz
About
Oliver Lenz is a scholar working on Hepatology, Epidemiology and Infectious Diseases.
According to data from OpenAlex, Oliver Lenz has authored 111 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 95 papers in Hepatology, 75 papers in Epidemiology and 26 papers in Infectious Diseases. Recurrent topics in Oliver Lenz's work include Hepatitis C virus research (95 papers), Hepatitis B Virus Studies (63 papers) and Liver Disease Diagnosis and Treatment (48 papers). Oliver Lenz is often cited by papers focused on Hepatitis C virus research (95 papers), Hepatitis B Virus Studies (63 papers) and Liver Disease Diagnosis and Treatment (48 papers). Oliver Lenz collaborates with scholars based in Belgium, United States and Germany. Oliver Lenz's co-authors include Monika Peeters, Maria Beumont‐Mauviel, Ronald Kalmeijer, Jane Scott, Guy De La Rosa, Sivi Ouwerkerk‐Mahadevan, Rekha Sinha, Thierry Verbinnen, Bart Fevery and Michael Fried and has published in prestigious journals such as The Lancet, Angewandte Chemie International Edition and Gastroenterology.
In The Last Decade
Oliver Lenz
107 papers receiving 4.3k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Oliver Lenz Belgium | 32 | 4.0k | 3.6k | 1.3k | 347 | 305 | 111 | 4.4k | ||
| Fiona McPhee United States | 29 | 3.2k 0.8× | 2.8k 0.8× | 1.2k 0.9× | 324 0.9× | 351 1.2× | 98 | 3.8k | ||
| Edward Tam United States | 38 | 5.8k 1.4× | 5.2k 1.4× | 2.1k 1.6× | 274 0.8× | 437 1.4× | 103 | 7.1k | ||
| William T. Symonds United States | 32 | 4.2k 1.0× | 3.8k 1.0× | 1.2k 0.9× | 311 0.9× | 306 1.0× | 89 | 4.9k | ||
| Jonathan McCone United States | 12 | 3.5k 0.9× | 3.1k 0.8× | 700 0.5× | 355 1.0× | 164 0.5× | 20 | 3.7k | ||
| Fernando Lopes Gonçales Brazil | 15 | 5.7k 1.4× | 5.0k 1.4× | 757 0.6× | 563 1.6× | 260 0.9× | 42 | 6.1k | ||
| Kenneth Koury United States | 14 | 6.3k 1.6× | 5.6k 1.5× | 854 0.6× | 644 1.9× | 296 1.0× | 29 | 6.8k | ||
| Nathalie Boyer France | 43 | 6.3k 1.6× | 6.2k 1.7× | 554 0.4× | 620 1.8× | 359 1.2× | 115 | 7.1k | ||
| Lindsay McNair United States | 20 | 2.4k 0.6× | 2.0k 0.6× | 696 0.5× | 293 0.8× | 190 0.6× | 37 | 2.8k | ||
| Hadas Dvory‐Sobol United States | 31 | 2.2k 0.6× | 2.0k 0.6× | 1.0k 0.8× | 135 0.4× | 356 1.2× | 98 | 3.1k | ||
| David Wyles United States | 31 | 2.0k 0.5× | 1.7k 0.5× | 865 0.7× | 137 0.4× | 396 1.3× | 110 | 2.6k |
Countries citing papers authored by Oliver Lenz
Since
Specialization
Citations
This map shows the geographic impact of Oliver Lenz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Oliver Lenz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Oliver Lenz more than expected).
Fields of papers citing papers by Oliver Lenz
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Oliver Lenz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Oliver Lenz. The network helps show where Oliver Lenz may publish in the future.
Co-authorship network of co-authors of Oliver Lenz
This figure shows the co-authorship network connecting the top 25 collaborators of Oliver Lenz. A scholar is included among the top collaborators of Oliver Lenz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Oliver Lenz. Oliver Lenz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Bömmel, Florian van, Thierry Verbinnen, Kosh Agarwal, et al.. (2025). Serum levels of hepatitis B core antibodies and hepatitis B core-related antigen at the time of nucleos(t)ide analog cessation and risk of severe flares in patients with chronic hepatitis B.. PubMed. 9(3).
2.
Liang, Xieer, Qiaoqiao Chen, Hong Tang, et al.. (2025). Prevalence of Hepatitis D Virus Antibody Positivity in Chinese Patients with Chronic Hepatitis B Virus Infection. Journal of Clinical and Translational Hepatology. 0(0). 0–0.
3.
Agarwal, Kosh, Marı́a Buti, Florian van Bömmel, et al.. (2024). JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2. Journal of Hepatology. 81(3). 404–414.
4.
Mak, Lung‐Yi, Christine I. Wooddell, Oliver Lenz, et al.. (2024). Long-term hepatitis B surface antigen response after finite treatment of ARC-520 or JNJ-3989. Gut. 74(3). 440–450.
5.
Peters, Marion G., Man‐Fung Yuen, Norah A. Terrault, et al.. (2023). Chronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug Classes. Clinical Infectious Diseases. 78(4). 983–990.
6.
Janssen, Harry L.A., Jinlin Hou, Tarik Asselah, et al.. (2023). Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection. Gut. 72(7). 1385–1398.
7.
Verbinnen, Thierry, Willem Talloen, Harry L.A. Janssen, et al.. (2023). Viral sequence analysis of chronic hepatitis B patients treated with the capsid assembly modulator JNJ-56136379 in the JADE phase 2a study. Antiviral Research. 216. 105660–105660.
8.
Ridder, Filip De, Milan J. Sonneveld, Oliver Lenz, et al.. (2021). Mean HBsAg decline at week 24 of PEG‐IFN‐based treatment predicts subsequent rate of HBsAg clearance — suggesting a valuable endpoint for early development HBV trials. Journal of Viral Hepatitis. 28(11). 1563–1569.
9.
Slaets, Leen, Filip De Ridder, Oliver Lenz, et al.. (2020). Systematic review with meta‐analysis: hepatitis B surface antigen decline and seroclearance in chronic hepatitis B patients on nucleos(t)ide analogues or pegylated interferon therapy. 2(3). 106–116.
10.
Verbinnen, Thierry, Willem Talloen, Jan Martin Berke, et al.. (2020). Virology analysis of chronic hepatitis B virus–infected patients treated for 28 days with JNJ‐56136379 monotherapy. Journal of Viral Hepatitis. 27(11). 1127–1137.
11.
Locarnini, Stephen, Bruce D. Given, Thomas Schluep, et al.. (2019). First clinical experience with RNA interference [RNAI]-based triple combination therapy in chronic hepatitis B (CHB): JNJ-73763989 (JNJ-3989), JNJ-56136379 (JNJ-6379) and a nucleos(t)ide analogue (NA). Hepatology. 70(6).
12.
Yuen, Man‐Fung, Edward Gane, Dong Joon Kim, et al.. (2019). Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection. Gastroenterology. 156(5). 1392–1403.e7.
13.
Lenz, Oliver, et al.. (2016). O2寛容性膜結合[NiFe]ヒドロゲナーゼのクリプトン誘導体化によりガス輸送のための疎水性のトンネルネットワークが解明される. Angewandte Chemie International Edition. 55(18). 5590.
14.
Kwo, Paul Y., Norman Gitlin, Ronald Nahass, et al.. (2016). Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. PMC.
15.
Gschwantler, Michael, G.J. Dore, M.P. Manns, et al.. (2014). Simeprevir (TMC435) with Peginterferon/Ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naïve european patients in the quest-1 and quest-2 phase III trials. Zeitschrift für Gastroenterologie. 52(5). 53.
16.
Ferenci, Péter, Xavier Forns, Eric Lawitz, et al.. (2014). Simeprevir (TMC435) with Peginterferon/Ribavirin for treatment of chronic HCV genotype 1 infection in european patients who relapsed after previous interferon-based therapy: the promise trial. Zeitschrift für Gastroenterologie. 52(5). 61.
17.
Lenz, Oliver, Leen Vijgen, Jan Martin Berke, et al.. (2012). Virologic response and characterisation of HCV genotype 2–6 in patients receiving TMC435 monotherapy (study TMC435-C202). Journal of Hepatology. 58(3). 445–451.
18.
Lenz, Oliver, Bart Fevery, Leen Vijgen, et al.. (2011). TMC435 IN COMBINATION WITH PEGINTERFERON ALPHA-2A/RIBAVIRIN IN TREATMENT-NAiVE PATIENTS INFECTED WITH HCV GENOTYPE 1: VIROLOGY ANALYSIS OF THE PILLAR STUDY. Hepatology. 54.
19.
Manns, Michael P., Yves Horsmans, Hendrik W. Reesink, et al.. (2008). Safety and Antiviral Activity of Tmc435350 in Treatment-name Genotype 1 Hcv-infected Patients. Hepatology. 48(4).
20.
Raboisson, Pierre, Tse‐I Lin, Herman de Kock, et al.. (2008). Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors. Bioorganic & Medicinal Chemistry Letters. 18(18). 5095–5100.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Fiona McPhee Breakdown of academic impact, for papers by Edward Tam Breakdown of academic impact, for papers by William T. Symonds Breakdown of academic impact, for papers by Jonathan McCone Breakdown of academic impact, for papers by Fernando Lopes Gonçales Breakdown of academic impact, for papers by Kenneth Koury Breakdown of academic impact, for papers by Nathalie Boyer Breakdown of academic impact, for papers by Lindsay McNair Breakdown of academic impact, for papers by Hadas Dvory‐Sobol Breakdown of academic impact, for papers by David Wyles